CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Total Edwards Lifesciences Corporation Stockholders' Equity	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2021			642.0
Beginning balance at Dec. 31, 2021	$ 5,835.9	$ 5,835.9	$ 642.0	$ (2,416.9)	$ 1,700.4	$ 6,068.1	$ (157.7)	$ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2021				17.9
Increase (Decrease) in Stockholders' Equity
Net income (loss)	1,521.9	1,521.9				1,521.9
Other comprehensive gain (loss), net of tax	(97.2)	(97.2)					(97.2)
Common stock issued under equity plans (in shares)			4.3
Common stock issued under equity plans	146.4	146.4	$ 4.3		142.1
Stock-based compensation expense	126.8	126.8			126.8
Purchases of treasury stock (in shares)				20.1
Purchases of treasury stock	(1,727.1)	(1,727.1)		$ (1,727.1)
Common stock, ending balance (in shares) at Dec. 31, 2022			646.3
Ending balance at Dec. 31, 2022	5,806.7	5,806.7	$ 646.3	$ (4,144.0)	1,969.3	7,590.0	(254.9)	0.0
Treasury stock, ending balance (in shares) at Dec. 31, 2022				38.0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	1,399.4	1,402.4				1,402.4		(3.0)
Other comprehensive gain (loss), net of tax	12.1	12.1					12.1
Common stock issued under equity plans (in shares)			4.2
Common stock issued under equity plans	169.9	169.9	$ 4.2		165.7
Stock-based compensation expense	139.4	139.4			139.4
Purchases of treasury stock (in shares)				11.4
Purchases of treasury stock	(880.5)	(880.5)		$ (880.5)
Changes to noncontrolling interest (Note 9)	$ 72.4							72.4
Common stock, ending balance (in shares) at Dec. 31, 2023	601.1		650.5
Ending balance at Dec. 31, 2023	$ 6,719.4	6,650.0	$ 650.5	$ (5,024.5)	2,274.4	8,992.4	(242.8)	69.4
Treasury stock, ending balance (in shares) at Dec. 31, 2023	49.4			49.4
Increase (Decrease) in Stockholders' Equity
Net income (loss)	$ 4,169.7	4,174.6				4,174.6		(4.9)
Other comprehensive gain (loss), net of tax	(1.7)	(1.7)					(1.7)
Common stock issued under equity plans (in shares)			4.3
Common stock issued under equity plans	179.5	179.5	$ 4.3		175.2
Stock-based compensation expense	163.8	163.8			163.8
Purchases of treasury stock (in shares)				16.8
Purchases of treasury stock	$ (1,167.8)	(1,167.8)		$ (1,167.8)
Common stock, ending balance (in shares) at Dec. 31, 2024	588.6		654.8
Ending balance at Dec. 31, 2024	$ 10,062.9	$ 9,998.4	$ 654.8	$ (6,192.3)	$ 2,613.4	$ 13,167.0	$ (244.5)	$ 64.5
Treasury stock, ending balance (in shares) at Dec. 31, 2024	66.2			66.2